Objective: Graves orbitopathy (GO) is an extrathyroidal manifestation of autoimmune thyroid disease. Early treatment with glucocorticoids in appropriately selected patients is recommended for active, moderate to severe, and sight-threatening disease. The recently published European Group on Graves Orbitopathy guidelines re-evaluated the recommended doses of intravenous methylprednisolone (ivMP) in response to the potential for adverse effects. We retrospectively reviewed our patient cohort treated with our ivMP protocol and analyzed the side effects of this treatment when given during hospitalization in our tertiary referral center.
Methods: Between May 2007 and May 2017, a total of 171 consecutive patients with active, moderate to severe, or sight-threatening GO were treated with ivMP in a cumulative dose of 7.5 grams, given monthly in three hospital sessions. Adverse events were reported using Version 4 of Common Terminology Criteria for Adverse Events.
Results: Ninety-two percent of patients who started the treatment were able to finish it; 5% did not finish the study due to adverse events, and 3% did not finish the treatment protocol because of noncompliance. The most common adverse events were asymptomatic changes in laboratory values (liver enzymes), psychiatric disorders, and infectious complications. None of the patients in the study died during the ivMP treatment, including those patients who experienced adverse effects or discontinued the protocol because of noncompliance.
Conclusion: High-dose ivMP for active, moderate to severe, and sight-threatening GO, when applied cautiously in carefully selected and monitored patients, is generally safe during the treatment period.
Abbreviations: AE = adverse effect; CAS = clinical activity score; CTCAE = Common Terminology Criteria for Adverse Events; DM = diabetes mellitus; EUGOGO = European Group on Graves Orbitopathy; GC = glucocorticoid; GO = Graves orbitopathy; ivMP = intravenous methylprednisolone.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4158/EP-2018-0047 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Simvastatin-Induced Ferroptosis in Orbital Fibroblasts in Graves' Ophthalmopathy.
Invest Ophthalmol Vis Sci
January 2025
Department of Ophthalmology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
Purpose: Graves' ophthalmopathy (GO), the most common extrathyroidal manifestation of Graves' disease, is disabling and disfiguring. Recent studies have shown that statins have a protective effect on individuals with GO. Statins were reported to trigger ferroptosis in some disorders, but little is known about whether statins protect against GO via ferroptosis.
View Article and Find Full Text PDFStudy on the correlation between serum IgG4/IgG levels and the development of Graves' ophthalmopathy.
Sci Rep
January 2025
Department of Endocrinology and Metabolism, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No.17 Yongwaizheng St, Nanchang, 330006, Jiangxi Province, People's Republic of China.
Graves' ophthalmopathy (GO) with elevated IgG4 levels has different characteristics from patients with GO who do not have elevated IgG4 levels, but the study findings are contradictory. The goal of this study was first to investigate the relationship between IgG4/IgG and IgG4 levels and the occurrence of GO and then to investigate the clinical and laboratory characteristics of patients with GO who had elevated IgG4 levels. This study control group consisted of 57 Graves' disease(GD)patients with no complicated ocular disease and a median followup of 54.
View Article and Find Full Text PDFHistogram of Apparent Diffusion Coefficient to Evaluate the Activity of Thyroid-Associated Ophthalmopathy.
Immun Inflamm Dis
January 2025
Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Objective: This study aimed to evaluate the activity of extraocular muscles (EOMs) in patients with thyroid-associated ophthalmopathy (TAO) using turbo spin echo imaging. By analyzing tissue heterogeneity, apparent diffusion coefficient (ADC) histogram analysis offers enhanced insights into edema within the EOMs.
Methods: Eighty-eight patients with TAO were retrospectively evaluated and allocated into active (n = 24, clinical activity score [CAS] ≥ 3) and inactive (n = 64, CAS < 3) groups.
The role of autophagy in Graves disease: knowns and unknowns.
Front Cell Dev Biol
January 2025
Department of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, Bisha, Saudi Arabia.
Graves disease (GD), an autoimmune disease affects the thyroid gland, results in hyperthyroidisms and goiter. The main cause of GD is not clearly defined; however, stimulating autoantibodies for thyroid stimulating hormone receptor (TSHR) known as thyroid-stimulating immunoglobulins (TSIs) are the primary proposed mechanism. The TSI activation of TSHRs of thyroid gland results in excessive release of thyroid hormones with the subsequent development of hyperthyroidism and goiter.
View Article and Find Full Text PDFTear film parameters in females with thyroid eye disease and diabetes: an observational study.
J Pak Med Assoc
January 2025
Department of Optometry, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
Objectives: To assess different tear film parameters in female patients with thyroid eye disease and diabetes using a single portable device.
Methods: The observational study was conducted at the College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia, from January 12 to April 28, 2022, and comprised women patients with thyroid eye disease in group A, women patients with diabetes in group B, and healthy controls in group C. The sample size was determined with a confidence level of 80% and a significance of 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!